Interested in specific Information?

Filter what you see here

General MM

Quick poll

EBMT 2019 | Real-world clinical experience of multiple myeloma induction…

EBMT 2019 | Real-world clinical experience of multiple myeloma induction regimens: subgroup analysis from the EMMOS study

Closes Apr 17, 2019

General MM

Quick poll

EBMT 2019 | The evolution of induction regimens in multiple myeloma

Closes Apr 16, 2019

General MM,   Relapsed/refractory patients

Quick poll

EBMT 2019 | High expansion level and long-term persistence of BCMA CAR T…

Closes Apr 9, 2019

Relapsed/refractory patients

Quick poll

Francesca Gay | ESH MM 2019 | Management of non-aggressive relapse…

Francesca Gay | ESH MM 2019 | Management of non-aggressive relapse 24-months post-transplant

Closes Apr 9, 2019

Relapsed/refractory patients

Quick poll

EMA grants anti-BCMA CAR T, JNJ-4528, PRIME designation in multiple…

Closes Apr 9, 2019

Patients eligible for transplant

Quick poll

EBMT 2019 | Dual-targeting CAR T-cells with autologous stem cell…

Closes Apr 8, 2019 , Expert Opinion

General MM

Quick poll

Angela Dispenzieri | ESH MM 2019 | Monoclonal gammopathy of clinical…

Angela Dispenzieri | ESH MM 2019 | Monoclonal gammopathy of clinical significance

Closes Apr 8, 2019

Patients non-eligible for transplant

Quick poll

Karthik Ramasamy | ESH MM 2019 | Treatment of first relapse in patients…

Closes Apr 7, 2019

Patients non-eligible for transplant,  

Quick poll

Sonja Zweegman | ESH MM 2019 | The impact of age on clinical…

Closes Apr 7, 2019

General MM

Quick poll

Sagar Lonial | ESH MM 2019 | The potential of CAR T therapy to replace…

Sagar Lonial | ESH MM 2019 | The potential of CAR T therapy to replace autologous stem cell transplantation

Closes Apr 7, 2019

General MM

Quick poll

Charlotte Pawlyn | ESH MM 2019 | Personalized treatment for patients with…

Closes Apr 6, 2019

General MM

Quick poll

Elena Zamagni | ESH MM 2019 | The use of imaging techniques in multiple…

Closes Apr 6, 2019

General MM

Quick poll

Jonathan Keats | ESH MM 2019 | Defining high-risk disease & treatment…

Jonathan Keats | ESH MM 2019 | Defining high-risk disease & treatment strategies in multiple myeloma

Closes Apr 5, 2019

General MM

Quick poll

Gareth Morgan | ESH MM 2019 | The impact of "double-hit" genetics on…

Closes Apr 5, 2019

Patients eligible for transplant

Quick poll

EBMT 2019 | Targeting NKG2D ligands in patients with multiple myeloma

Closes Apr 5, 2019
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Congress Coverage

Patients eligible for transplant

EBMT 2019 | Dual-targeting CAR T-cells with autologous stem cell transplant for high-risk…

Apr 8, 2019 , Expert Opinion
English & Italian

Latest Biology

English & Dutch
Patients non-eligible for transplant,

Sonja Zweegman | ESH MM 2019 | The impact of age on clinical decision-making

Apr 7, 2019

Latest Drug Updates

Relapsed/refractory patients,Patients non-eligible for transplant

Positive EMA CHMP opinion for two new triplet regimens in multiple myeloma

Apr 3, 2019
General MM,Patients non-eligible for transplant,Patients eligible for transplant

US Food and Drug Administration and European Medicines Agency approvals sought for new…

Apr 3, 2019

Recently updated Licenses

Where we are next

ESH: 2nd How to Diagnose and Treat Multiple Myeloma

April 5 – 7, 2019 | Berlin, Germany

The Multiple Myeloma Hub will be attending the 2nd How to Diagnose and Treat Multiple Myeloma meeting of the European School of Haematology (ESH) in Berlin, Germany. We will be conducting interviews with world-leading experts, presenting live coverage via our social media channels and providing summaries of key sessions. Stay tuned to follow our first-hand coverage.

#mmsm #myeloma 

Event Website

Map Data
Map data ©2019 GeoBasis-DE/BKG (©2009), Google
Map DataMap data ©2019 GeoBasis-DE/BKG (©2009), Google
Map data ©2019 GeoBasis-DE/BKG (©2009), Google

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology